Perrigo’s Loss Is Lupin’s Gain On Albuterol
As Lupin’s Somerset Site Gets 13 Observations Following FDA Inspection
Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.
You may also be interested in...
Sun Pharma is looking to target a market worth $136m after receiving US FDA approval for amphotericin B liposome with a Competitive Generic Therapy designation, bringing the promise of 180 days of CGT exclusivity for the product.
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.